Transparens och offentliga deklarationer

Norgine Pty Ltd is a member company of Medicines Australia and fully complies with the Medicines Australia Code of Conduct reporting requirements on transfers of value to healthcare professionals (HCPs) and  health consumer organisations (HCOs). 

Please click below for Norgine’s latest Payments to Healthcare Professionals reports (these reports may also include payments to New Zealand HCPs or HCOs – see New Zealand section below):

Please click below for Norgine’s latest Sponsorship of 3^rd Party Meetings report:

Please click below for Norgine’s latest Health Consumer Organisation Support report:

Norgine is working towards full compliance with Pharmig VHC requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value: 2019, 2018, 2017 

Methodology note: 2019, 2018, 2017

Norgine is working towards full compliance with Pharmig VHC requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same. https://www.betransparent.be/en/

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value and Methodology Notes for 2019, 2018 and 2017 are publicly available on https://www.betransparent.be/en/ as of July 1st after the reference year.

Norgine is working towards full compliance with Pharma Industry Denmark (LIF) and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value: 2020, 2019, 2018

Methodology note: 2020, 2019, 2018

Norgine acquired Azanta in March 2020.  See Azanta’s transfers of value for the years 2017, 2018 and 2019 here and click here for the methodology notes

Norgine’s consultancy payments to healthcare professionals, sponsorships to attend scientific meetings and congresses, and grants and donations to healthcare organisations in Ireland are made in line with the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice for the Pharmaceutical Industry.

The IPHA code also mentions Research and development ToV – Research and Development Transfers of Value in each reporting period shall be disclosed by each company on an aggregate basis. Costs related to events that are clearly related to activities covered in this section can be included in the aggregate amount under the “Research and Development Transfers of Value” category.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value: No ToV to publish in 2019 or 2018, 2017

Methodology note: No ToV to publish in 2019 or 2018, 2017

Norgine is working towards full compliance with Pharma Industry Finland (PIF) and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value: 2020, 2019, 2018

Methodology note: 2020, 2019, 2018

Norgine acquired Azanta in March 2020.  See Azanta’s transfers of value for the years 2017, 2018 and 2019 here and click here for the methodology notes

TRANSPARENCE DES LIENS D’INTERET – France

NORGINE Pharma renommé NORGINE SAS, 2 rue Jacques Daguerre, 92500 RUEIL MALMAISON

Date de mise à jour :  Juin 2020

Conformément à la loi n°2011-2012 du 29 décembre 2011 relative au renforcement de la sécurité sanitaire du médicament et des produits de santé, et à son décret d’application n°2013-414 du 21 mai 2013, NORGINE SAS doit rendre publiques les informations relatives aux avantages consentis (supérieurs ou égaux à 10€) et aux conventions ou contrats conclus avec les professionnels et organisations de santé.

Conformément au décret du 28 décembre 2016 et l’arrêté du 22 mars 2017, Norgine SAS doit publier les rémunérations perçues par l’ensemble des acteurs de santé concernés, et ce, dès le 1er octobre 2017.

La publication des données concernant les conventions et le montant des avantages perçus a lieu sur le site internet public unique mis en place par le Ministère de la Santé : https://www.transparence.sante.gouv.fr

Conformément à la publication des informations sur le site public, et conformément à la loi « Informatique et Libertés » du 6 janvier 1978 modifiée, les professionnels de santé disposent d’un droit d’accès et de rectification des données personnelles qui les concernent. Pour exercer ce droit, merci de nous contacter via l’adresse : healthcare-expense-support@norgine.com.

Norgine a fait l’acquisition d’ Azanta en mars 2020. Les informations relatives aux avantages consentis (supérieurs ou égaux à 10€) et aux conventions ou contrats conclus par Azanta avec les professionnels et organisations de santé français jusqu’au 1^er semestre 2020 sont accessible sur le site internet public unique https://www.transparence.sante.gouv.fr

Norgine is working towards full compliance with AKG-Transparenzregel requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value: 2019, 2018, 2017

Methodology note: 2019, 2018, 2017

Norgine is working towards full compliance with Farmindustria and national law requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value: 2019, 2018, 2017

Methodology note: 2019, 2018, 2017

Norgine is working towards full compliance with Transparantie Zorg, CGR and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

http://www.transparantieregister.nl/nl-NL/Home (Dutch version)
http://www.transparantieregister.nl/en-GB/Home (English version)

Methodology note: 2019, 2018, 2017

The costs for research and development (R&D) have not been incorporated in the above mentioned transparency register. Nonetheless, in order to be as transparent as possible it has been the decision by EFPIA that European pharma companies should publish these R&D costs made in the respective countries on their website in an aggregate manner.  In 2019, there was no R&D costs for Norgine in the Netherlands. In the Netherlands, the R&D work and thus the aggregated amount is usually rather limited as most R&D is performed internationally outside the Netherlands.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Norgine is not a member of Medicines New Zealand, and the current Medicines New Zealand Code of Conduct does not contain any transparency or reporting requirements.

Norgine’s has a limited presence in New Zealand, and if any transfers of value are made from Norgine Pty Ltd  to New Zealand HCP or HCOs, they  would be included in our reports to Medicines Australia.

For New Zealand, Norgine Pty Ltd applies the same reporting requirements as for Australia; the data can be accessed by clicking on the Australian flag.

Norgine is working towards full compliance with Pharmaceutical Industry in Norway (LMI) and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value: 2020, 2019, 2018

Methodology note: 2020, 2019, 2018

Patient Organisations/Donations: no interactions in 2020, 2019 or 2018

Norgine acquired Azanta in March 2020.  See Azanta’s transfers of value for the years 2017, 2018 and 2019 here and click here for the methodology notes

Norgine is working towards full compliance with EFPIA requirements to report relevant transfers of value to healthcare professionals and healthcare organisations, even in territories where it has not got a physical presence or a sales and marketing Affiliate.  

Please click on the following links to consult recent transfers of value in Poland as well as the methodology notes providing further insight.

Should you have any query related to the reported transfers of value, please contact us via contact details listed towards the end of our methodology notes.

Transfers of value: No ToV to publish in 2019, 2018, no ToV to publish in 2017

Methodology note: No ToV to publish in 2019, 2018, no ToV to publish in 2017

Norgine is working forwards full compliance with FARMAINDUSTRIA and EFPIA requirements to report payments and transfer of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfer of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value: 2019, 2018, 2017

Methodology note: 2019, 2018, 2017 

AVISO LEGAL

La publicación de estos datos responde a las obligaciones de transparencia derivadas del Código de Buenas Prácticas de la Industria Farmacéutica.

De la publicación de la información no se deriva una habilitación general para que quienes accedan al sitio web puedan llevar a cabo un tratamiento adicional de los datos de los profesionales, tales como su cruce con las informaciones publicadas en los sitios web de otros asociados.

Norgine de España S.L.U. ha adoptado medidas de seguridad para evitar la indexación de la información a través de motores de búsqueda.

Norgine is working towards full compliance with Läkemedelsindustriföreningen and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.

Transfers of value: 2020, 2019, 2018

Methodology note: 2020, 2019, 2018

Norgine acquired Azanta in March 2020.  See Azanta’s transfers of value for the years 2017, 2018 and 2019 here and click here for the methodology notes

Norgine is working towards full compliance with Pharma-Kodex and Pharma-Kooperations-Kodex requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Any transfers of value made to HCPs or HCOs from Liechtenstein are disclosed together with the data from Switzerland.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology notes.

Transfers of value: 2019, 2018, 2017

Methodology note: 2019, 2018, 2017

Norgine’s consultancy payments to healthcare professionals, sponsorships to attend scientific meetings and congresses, and grants and donations to healthcare organisations in the UK are made in line with the Association of British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry.

Please click on the following link to view the same.

www.disclosureuk.org.uk